{
  "id": "5e48a916d14c9f295d00000f",
  "type": "factoid",
  "question": "Which receptor is modulated with Siponimod?",
  "ideal_answer": "Siponimod is a functional sphingosine-1-phosphate (S1P) antagonist.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24900670",
    "http://www.ncbi.nlm.nih.gov/pubmed/29627873",
    "http://www.ncbi.nlm.nih.gov/pubmed/25580263",
    "http://www.ncbi.nlm.nih.gov/pubmed/29576505",
    "http://www.ncbi.nlm.nih.gov/pubmed/31558140",
    "http://www.ncbi.nlm.nih.gov/pubmed/28990207",
    "http://www.ncbi.nlm.nih.gov/pubmed/29500302",
    "http://www.ncbi.nlm.nih.gov/pubmed/31603362",
    "http://www.ncbi.nlm.nih.gov/pubmed/31290453",
    "http://www.ncbi.nlm.nih.gov/pubmed/25924727",
    "http://www.ncbi.nlm.nih.gov/pubmed/29310513",
    "http://www.ncbi.nlm.nih.gov/pubmed/26856814",
    "http://www.ncbi.nlm.nih.gov/pubmed/23764350",
    "http://www.ncbi.nlm.nih.gov/pubmed/29110882",
    "http://www.ncbi.nlm.nih.gov/pubmed/31009359",
    "http://www.ncbi.nlm.nih.gov/pubmed/29138536",
    "http://www.ncbi.nlm.nih.gov/pubmed/29205338",
    "http://www.ncbi.nlm.nih.gov/pubmed/29556671",
    "http://www.ncbi.nlm.nih.gov/pubmed/25223691",
    "http://www.ncbi.nlm.nih.gov/pubmed/31144287",
    "http://www.ncbi.nlm.nih.gov/pubmed/28752787",
    "http://www.ncbi.nlm.nih.gov/pubmed/29735753",
    "http://www.ncbi.nlm.nih.gov/pubmed/27566665"
  ],
  "snippets": [
    {
      "text": "RESULTS: Among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28752787",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28752787",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sphingosine 1-phosphate (S1P1 ) modulators provide an emerging therapeutic approach for various autoimmune disorders such as multiple sclerosis and psoriasis. Fingolimod is the first approved orally active, selective and potent drug of this class. Other drugs belonging to this class include siponimod, ponesimod, ceralifimod, amiselimod, CS-0777 and GSK2018682. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28990207",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29205338",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Functional sphingosine-1-phosphate (S1P) antagonists like fingolimod and siponimod (BAF312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (EAMG), the standard model of MG.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29205338",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thus, the aim of this study was to characterize the immunomodulatory effect of the functional S1PR1 antagonist, siponimod, in phase III clinical trials for autoimmune disorders and of the competitive sphingosine 1-phosphate receptor subtype 1 (S1PR1) antagonist, TASP0277308, in pre-clinical development in an in vivo model of TBI in mice. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310513",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition, there are three more specific S1P agonists in late stages of development: siponimod, ponesimod, and ozanimod.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29500302",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We assessed the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor1,5 modulator, on disability progression in patients with SPMS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29576505",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod, a selective sphingosine-1-phosphate receptor modulator, reduced 3-month CDP by 21% versus placebo in SPMS. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29627873",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A high incidence of hemangiosarcoma (HSA) was observed in mice treated for 2\u00a0years with siponimod, a sphingosine-1-phosphate receptor 1 (S1P1) functional antagonist, while no such tumors were observed in rats under the same treatment conditions. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29556671",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod (BAF312), a selective sphingosine 1-phosphate1,5 receptor modulator, is currently under investigation in a clinical trial in secondary progressive MS patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27566665",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BAF312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in PMS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31290453",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\n\nSiponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5, with an elimination half-life leading to washout in 7 days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23764350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31290453",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siponimod is an S1PR (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31009359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29735753",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod is a newer-generation sphingosine 1 phosphate (S1P) receptor modulator that internalizes S1P1 receptors, thereby inhibiting efflux of lymphocytes from lymph nodes and thymus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31603362",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900670",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siponimod is a newer-generation sphingosine 1 phosphate ( S1P ) receptor modulator that internalizes S1P1 receptors , thereby inhibiting efflux of lymphocytes from lymph nodes and thymus",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31603362",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod ( Mayzent ) is an oral selective sphingosine 1-phosphate receptor subtypes 1 and 5 ( S1PR ) modulator being developed by Novartis Pharmaceuticals for the treatment of multiple sclerosis ( MS ) and intracerebral haemorrhage",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31144287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Similar to fingolimod , siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29110882",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod is an S1PR ( sphingosine-1-phosphate receptor ) modulator , which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31009359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of BAF312 ( Siponimod) , a Potent and Selective S1P Receptor Modulator",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900670",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Proof-of-concept studies across validated animal models with S1P receptor modulators highly selective for S1P1 , such as BAF-312 ( Siponimod) , KRP-203 , ONO-4641 ( Ceralifimod) , ponesimod and RPC-1063 , and emerging clinical trials for safety and efficacy in humans , particularly in MS , ulcerative colitis ( UC ) and psoriasis , have set the stage for us to consider additional testing in various other autoimmune diseases",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580263",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BAF312 ( siponimod ) is a sphingosine-1-phosphate ( S1P ) receptor modulator in clinical development for the treatment of multiple sclerosis , with faster organ/tissue distribution and elimination kinetics than its precursor FTY720 ( fingolimod",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25924727",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Functional sphingosine-1-phosphate (S1P) antagonists like fingolimod and siponimod (BAF312) are successfully used for the treatment of multiple sclerosis, and fingolimod was shown to prevent the development of myasthenic symptoms in experimental autoimmune myasthenia gravis (EAMG), the standard model of MG.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29205338",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod (BAF312), a selective sphingosine 1-phosphate1,5 receptor modulator, is currently under investigation in a clinical trial in secondary progressive MS patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27566665",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod is an S1PR (sphingosine-1-phosphate receptor) modulator, which blocks the egress of lymphocytes from lymphoid organs and has demonstrated beneficial effects in multiple sclerosis treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31009359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate (S1P) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of B and T cells in secondary lymphoid organs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29138536",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Siponimod reduced the risk of disability progression with a safety profile similar to that of other S1P modulators and is likely to be a useful treatment for SPMS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29576505",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Compared to fingolimod (ie, precursor of the S1P modulators commercially available for the treatment of relapsing-remitting [RR] multiple sclerosis [MS]), siponimod exhibits selective affinity for types 1 and 5 S1P receptor, leading to a lower risk of adverse events that are mainly induced by S1P3 receptor activation, such as bradycardia and vasoconstriction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29138536",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study, we directly compared the electropharmacological profiles of fingolimod with those of siponimod, a modulator of sphingosine 1-phosphate receptor subtype 1 and 5, using in vivo guinea-pig model and in vitro human ether-a-go-go-related gene (hERG) assay to better understand the onset mechanisms of the clinically observed adverse events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25223691",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BAF312 (Siponimod) is a dual agonist at the sphingosine-1 phosphate receptors, S1PR1 and S1PR5.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26856814",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BAF312 (siponimod) is a sphingosine-1-phosphate (S1P) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor FTY720 (fingolimod).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25924727",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod, a selective modulator of sphingosine 1-phosphate receptors type 1 and type 5, demonstrated an excellent safety profile in a large study of patients with multiple sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31558140",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siponimod (BAF312), a selective sphingosine 1-phosphate1,5 receptor modulator, is currently under investigation in a clinical trial in secondary progressive MS patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27566665",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "sphingosine-1-phosphate"
}